Author:
Pérez-Cabello Jesús A.,Silvera-Carrasco Lucía,Franco Jaime M.,Capilla-González Vivian,Armaos Alexandros,Gómez-Lima María,García-García Raquel,Yap Xin Wen,Leal-Lasarte M. Magdalena,Lall Deepti,Baloh Robert H.,Martínez Salvador,Miyata Yoshihiko,Tartaglia Gian G.,Sawarkar Ritwick,García-Dominguez Mario,Pozo David,Roodveldt Cintia
Abstract
AbstractAmyotrophic lateral sclerosis (ALS) is a fatal and incurable neurodegenerative disease affecting motor neurons and characterized by microglia-mediated neurotoxic inflammation whose underlying mechanisms remain incompletely understood. In this work we reveal that MAPK/MAK/MRK overlapping kinase (MOK), with unknown physiological substrate, displays an immune function by controlling inflammatory and type-I IFN responses in microglia which are detrimental to primary motor neurons. Moreover, we uncover the epigenetic reader bromodomain-containing protein 4 (Brd4) as the first molecule regulated by MOK, by promoting Ser492-phospho-Brd4 levels. We further demonstrate that MOK regulates Brd4 functions by supporting its binding to cytokine gene promoters, therefore enabling innate immune responses. Remarkably, we show that MOK levels are increased in ALS spinal cord, particularly in microglial cells, and that administration of a chemical MOK-inhibitor to ALS model mice is able to modulate Ser492-phospho-Brd4 levels, suppress microglial activation and modify disease course, indicating a pathophysiological role of MOK kinase in ALS and neuroinflammation.
Publisher
Cold Spring Harbor Laboratory